Stephen R. Kraus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen R. Kraus has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Toby C. Chai
Department of Urology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA; Department of Urology, Boston Medical Center, Boston, MA, USA
3 shared publications Gary E. Lemack
Department of Urology, University of Texas Southwestern, Dallas, TX
2 shared publicationsHeather J. Litman
10New England Research Institutes, Watertown, MA
2 shared publications- Holly Elizabeth Richter
University of Alabama at Birmingham
2 shared publications Larry T. Sirls
Department of Urology, Beaumont Hospital, Michigan
2 shared publicationsLei Xu
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
2 shared publications
Latest Publications
- 1 January 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (1) , 22-24
Long-term Efficacy and Safety of Questionnaire-Based Initiation of Urgency Urinary Incontinence Treatment
A large number of women with urinary incontinence do not receive appropriate care because of delays in diagnosis resulting from failure of primary care providers to ask routine questions about incontinence as well as failure of patients to volunteer information. Diagnosis of incontinence only after referral to specialists increases the cost of care and delays treatment. A simple, brief questionnaire-based screening instrument has been developed to allow primary care providers to diagnose and treat urgency-predominant urinary incontinence (UUI) in women without more extensive specialist evaluation. The longer-term efficacy and safety of treating patients with incontinence based on this questionnaire are unknown. This open-label multicenter study was designed to determine the longer-term efficacy and safety of initiating treatment for women with UUI diagnosed using the questionnaire rather than an extensive evaluation. The study was conducted between February 2009 and January 2010. Participants were 567 women who completed a 12-week placebo-controlled randomized trial of an antimuscarinic drug for UUI diagnosed by a questionnaire; 498 (87.8%) of these women agreed to enroll in a preplanned 9-month, open-label continuation study. The antimuscarinic used in both the randomized portion and open-label portion of the study was fesoterodine administered daily. Participants were seen in person at the open-label baseline and at 1, 3, 6, and 9 months and were contacted by telephone at 2 weeks. Safety was assessed by measuring post void residual volume and monitoring adverse events; when necessary, women were evaluated by a specialist. Linear mixed models with adjustment for baseline were used to evaluate longitudinal changes in UUI and voiding episodes. At the end of the open-label study, compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day (adjusted mean [SE], 4.6 [0.12] reduced to 1.2 [0.13]) and urgency incontinence episodes per day (3.9 [0.11] reduced to 0.9 [0.11]; P < .0001 for both). Most women who continued in the open-label study were satisfied with treatment (89%, 92%, and 93% at 3, 6, and 9 months, respectively). A total of 28 serious adverse events were experienced by 26 women; only 1 case was considered to be possibly related to treatment. During the open-label study, 83 women were offered extended evaluations. Of the 22 women who completed extended evaluations, only 5 were considered by the specialist to be misclassified by the incontinence questions; none of these patients experienced harm because of the misclassification. These findings demonstrate the safety and effectiveness of using a simple validated questionnaire to diagnose and initiate treatment for UUI in a population of community-dwelling women. The data suggest that use of the questionnaire is likely to allow timely treatment in a primary care setting of many patients with UUI without the need for referral to a specialist.
- 1 January 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (1) , 22-24
Long-term Efficacy and Safety of Questionnaire-Based Initiation of Urgency Urinary Incontinence Treatment
A large number of women with urinary incontinence do not receive appropriate care because of delays in diagnosis resulting from failure of primary care providers to ask routine questions about incontinence as well as failure of patients to volunteer information. Diagnosis of incontinence only after referral to specialists increases the cost of care and delays treatment. A simple, brief questionnaire-based screening instrument has been developed to allow primary care providers to diagnose and treat urgency-predominant urinary incontinence (UUI) in women without more extensive specialist evaluation. The longer-term efficacy and safety of treating patients with incontinence based on this questionnaire are unknown. This open-label multicenter study was designed to determine the longer-term efficacy and safety of initiating treatment for women with UUI diagnosed using the questionnaire rather than an extensive evaluation. The study was conducted between February 2009 and January 2010. Participants were 567 women who completed a 12-week placebo-controlled randomized trial of an antimuscarinic drug for UUI diagnosed by a questionnaire; 498 (87.8%) of these women agreed to enroll in a preplanned 9-month, open-label continuation study. The antimuscarinic used in both the randomized portion and open-label portion of the study was fesoterodine administered daily. Participants were seen in person at the open-label baseline and at 1, 3, 6, and 9 months and were contacted by telephone at 2 weeks. Safety was assessed by measuring post void residual volume and monitoring adverse events; when necessary, women were evaluated by a specialist. Linear mixed models with adjustment for baseline were used to evaluate longitudinal changes in UUI and voiding episodes. At the end of the open-label study, compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day (adjusted mean [SE], 4.6 [0.12] reduced to 1.2 [0.13]) and urgency incontinence episodes per day (3.9 [0.11] reduced to 0.9 [0.11]; P < .0001 for both). Most women who continued in the open-label study were satisfied with treatment (89%, 92%, and 93% at 3, 6, and 9 months, respectively). A total of 28 serious adverse events were experienced by 26 women; only 1 case was considered to be possibly related to treatment. During the open-label study, 83 women were offered extended evaluations. Of the 22 women who completed extended evaluations, only 5 were considered by the specialist to be misclassified by the incontinence questions; none of these patients experienced harm because of the misclassification. These findings demonstrate the safety and effectiveness of using a simple validated questionnaire to diagnose and initiate treatment for UUI in a population of community-dwelling women. The data suggest that use of the questionnaire is likely to allow timely treatment in a primary care setting of many patients with UUI without the need for referral to a specialist.
- 1 September 2010
- Published by Springer Nature in Drugs & Aging
- Vol. 27 (9) , 697-713
Vulnerable Elderly Patients and Overactive Bladder Syndrome
Overactive bladder (OAB) prevalence increases with age, and the elderly population is rapidly increasing worldwide, particularly those aged ≥75 years. OAB symptoms may be associated with co-morbid...
- 1 September 2010
- Published by Springer Nature in Drugs & Aging
- Vol. 27 (9) , 697-713
Vulnerable Elderly Patients and Overactive Bladder Syndrome
Overactive bladder (OAB) prevalence increases with age, and the elderly population is rapidly increasing worldwide, particularly those aged ≥75 years. OAB symptoms may be associated with co-morbid...
- 25 June 2010
- Published by Wiley in Neurourology and Urodynamics
- Vol. 29 (5) , 741-747
Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction
Aims: To present the methodology, standardization techniques, and results from post hoc test–retest reproducibility analyses for a large, placebo‐controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO).Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [pdetQmax]), and test–retest reproducibility of the placebo arm at baseline and endpoint.Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≥13) at 20 sites were randomized to receive either tadalafil 20 mg or placebo. All men underwent non‐invasive uroflow and pressure‐flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of pdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure‐flow parameters including pdetQmax (r = .83).Conclusions: Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter‐site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test–retest reproducibility of pressure flow measures. Neurourol. Urodynam. 29:741–747, 2010.
- 25 June 2010
- Published by Wiley in Neurourology and Urodynamics
- Vol. 29 (5) , 741-747
Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction
Aims: To present the methodology, standardization techniques, and results from post hoc test–retest reproducibility analyses for a large, placebo‐controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO).Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [pdetQmax]), and test–retest reproducibility of the placebo arm at baseline and endpoint.Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≥13) at 20 sites were randomized to receive either tadalafil 20 mg or placebo. All men underwent non‐invasive uroflow and pressure‐flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of pdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure‐flow parameters including pdetQmax (r = .83).Conclusions: Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter‐site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test–retest reproducibility of pressure flow measures. Neurourol. Urodynam. 29:741–747, 2010.
- Open Access
- 1 May 2009
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 3, 151-161
Oxybutynin extended release for the management of overactive bladder: a clinical review
Oxybutynin extended release for the management of overactive bladder: a clinical review AM Arisco, EK Brantly, SR KrausUniversity of Texas Health Science Center at San Antonio, Department of Urology, San Antonio, Texas, USA Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.Keywords: overactive bladder, urinary urge incontinence, antimuscarinic, oxybutynin
- 1 May 2009
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 3, 151-161
Open AccessOxybutynin extended release for the management of overactive bladder: a clinical review
Oxybutynin extended release for the management of overactive bladder: a clinical review AM Arisco, EK Brantly, SR KrausUniversity of Texas Health Science Center at San Antonio, Department of Urology, San Antonio, Texas, USA Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.Keywords: overactive bladder, urinary urge incontinence, antimuscarinic, oxybutynin
- 29 March 2008
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 3 (1) , 19-25
A critical review of mesh kits for prolapse repairs
- 29 March 2008
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 3 (1) , 19-25
A critical review of mesh kits for prolapse repairs
- 1 July 2007
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 197 (1) , 92.e1-92.e6
Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery
- 1 July 2007
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 197 (1) , 92.e1-92.e6
Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery